The Trop-2 directed antibody drug conjugate datopotamab deruxtecan demonstrated a statistically significant improvement in progression-free survival vs docetaxel in patients with advanced or metastatic non–small cell lung cancer, however those with squamous histology did not experience a benefit.
Datopotamab deruxtecan not only demonstrated a statistically significant improvement over chemotherapy for breast cancer and docetaxel for non–small cell lung cancer (NSCLC), but the intervention therapy had less toxicity.
Positive results from the pivotal TROPION-Lung01 Phase III trial showed that datopotamab deruxtecan demonstrated a statistically significant improvement for the primary endpoint of.
High Translation Costs Hinder Minority Participation in Trials miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.